Privately-held US biotech Skyhawk Therapeutics has announced a strategic research collaboration with Germany’s Merck KGaA ...

Adding another name to an impressive roster of partners assembled over the past few years, Skyhawk Therapeutics Inc. inked a neurology-focused deal with Merck KGaA aimed at discovering small-molecule ...

Skyhawk's RNA tech could be Merck's next blockbuster play as drug setbacks and looming patent cliffs force a reinvention.

Waltham, Massachusetts–based Skyhawk Therapeutics has been collecting collaborations with larger companies in spades since ...

Merck KGaA has swooped into a neurological-focused pact with RNA biotech Skyhawk Therapeutics that could top out at $2 ...

Merck KGaA agreed to collaborate with Skyhawk Therapeutics Inc. to develop neurological therapies in a deal that could be ...

Skyhawk recently started dosing patients in its phase 2/3 FALCON-HD trial of lead candidate SKY-0515, involving patients with ...

Skyhawk Therapeutics enters into an option agreement to grant Merck exclusive global rights to drug candidates pursued under the collaboration upon option exercise Total deal value exceeds ...

“What do we make of the numbers that we got from Merck this morning? The pharma titan reported what some thought was a mixed quarter. I actually liked it.

US pharmaceutical company Merck announced on Tuesday that it would cut jobs as part of a cost-reduction plan aimed at saving $3 billion annually by 2027.

Merck said it is embarking on a multi-year cost-savings plan, which includes cuts to its workforce and real-estate footprint, as it looks to redirect resources toward new product launches.

[DARMSTADT] Drugmaker Merck on Tuesday (Jul 29) announced job and cost cuts it said will save US$3 billion a year as it posted lower second-quarter results due to continuing weak demand for its ...